Table 3

Immunotherapy duration, clinical follow-up, immunotherapy termination

Nivolumab+TACE
(n=31)
Nivolumab only
(All matched n=104)
Number (%) or median (Range)P value
Duration immunotherapy (months)8.3 (0.5–40.1)3.3 (0.4–35.9)0.009*
Clinical follow-up after nivolumab initiation (months)12.6 (1.3–40.6)7.5 (0.5–47.8)0.26
Ongoing nivolumab at last follow-up13 (42)23 (22)0.04
Discontinued treatment18 (58)80 (77)0.07
 Disease progression3 (9.7)39 (38)0.004*
 Study drug toxicity0 (0)9 (8.7)0.12
 Complete Response1 (3.2)1 (1.0)0.41
 Clinical deterioration4 (13)2 (1.9)0.03†
 Death5 (16)‡3 (2.9)0.02†
 Other5 (16)§14 (13)*0.77
  • *Statistically significant p-value <0.01

  • †Statistically significant p-value <0.05

  • ‡2/5 deaths in setting of progression of disease

  • §4 patients successfully bridged to transplant.

  • TACE, transarterial chemoembolization.